SOURCE: Recombinant Data Corporation

Recombinant Data Corporation

January 31, 2012 14:00 ET

Recombinant Data Executive Re-Elected to Clinical Data Interchange Standards Consortium (CDISC) Board of Directors

Dr. David Hardison to Help Shape Healthcare Data Standards to Advance Personalized Medicine

NEWTON, MA--(Marketwire - Jan 31, 2012) - Recombinant Data, a healthcare data warehousing and clinical intelligence solutions provider, today announced that David Hardison, PhD, managing director, Health Sciences, has been re-elected to serve on the Clinical Data Interchange Standards Consortium (CDISC) Board of Directors and will chair the Financial Oversight Committee. CDISC is a non-profit organization which develops and supports global, platform-independent data standards that enable information system interoperability to improve medical and life sciences research with a vision to inform patient care and safety through higher quality medical research. Hardison will join the other directors in providing strategic guidance for CDISC's major 2012 initiatives, including steps towards translational medicine. Linking data from patient care, clinical research and basic life science research is critical to advancing personalized medicine.

"CDISC has reached an exciting point in its history and we're pleased that David will serve another term on CDISC's Board of Directors. He will continue to help advance our mission to develop global, open and vendor neutral data standards that improve the efficiency of clinical research," said Rebecca Kush, PhD, CDISC president and CEO. "David's expertise in healthcare delivery and pharmaceutical research aligns with CDISC's strategic objective of fostering information sharing between life science researchers and healthcare delivery around the world." CDISC focal points include programs such as the Innovative Medicines Initiative (IMI) EHR4CR project. Launched in 2011, EHR4CR comprises public-private partnerships to provide adaptable, reusable and scalable solutions for reusing data from electronic health record systems for clinical research. Other developing translational research projects CDISC will explore include European Translational Information and KM Services (eTRIKS).

Hardison has more than 30 years of leadership experience and knowledge at the intersection of biopharmaceutical R&D, healthcare delivery, performance improvement, and information technology. He focuses on strategic consulting and business development for Recombinant clients in life sciences and healthcare, and is responsible for overseeing Recombinant's growing presence in the European Union.

"I am honored to continue my association with CDISC as the organization enters its second decade. The convergence of healthcare delivery and the biopharmaceutical industry around personalized medicine creates even more demands for interoperable standards for the integration and exchange of clinical and genomic data," said Hardison. "CDISC's work is crucial to connecting and extracting the value of information from all stakeholders in the healthcare lifecycle. This work has the potential to accelerate innovation, dramatically improve patient outcomes and quality life, and contain discovery and delivery costs."

CDISC is a global, open, multidisciplinary, neutral non-profit organization that has established standards to support the acquisition, exchange, submission and archive of clinical/medical research data and metadata through a consensus-based process. The CDISC mission is to develop and support global, platform-independent data standards that enable information system interoperability to improve medical research and related areas of healthcare. The CDISC Vision: Informing patient care and safety through higher quality medical research. CDISC standards are open and freely available via the CDISC website. Additional information on CDISC can be accessed at

About Recombinant Data Corporation

Recombinant provides leading-edge data warehousing and clinical intelligence solutions to healthcare providers, academic medical centers and life science researchers to deliver higher quality outcomes, accelerate personalized medicine, and lower costs. Our team of industry veterans is focused on improving the flow of reliable data to power clinical and research applications in a secure, compliant environment. For more information about Recombinant's products and services, visit

Contact Information